Brokerages predict that Tricida Inc (NASDAQ:TCDA) will post ($0.80) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tricida’s earnings. The highest EPS estimate is ($0.79) and the lowest is ($0.80). The business is expected to report its next earnings results on Thursday, June 27th.
According to Zacks, analysts expect that Tricida will report full-year earnings of ($3.34) per share for the current financial year, with EPS estimates ranging from ($3.45) to ($3.22). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.52) to ($3.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Tricida.
Tricida (NASDAQ:TCDA) last announced its earnings results on Thursday, March 28th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.23.
Shares of Tricida stock traded down $0.09 during trading on Monday, reaching $32.74. The company’s stock had a trading volume of 550,800 shares, compared to its average volume of 339,722. The stock has a market capitalization of $1.40 billion and a price-to-earnings ratio of -7.06. Tricida has a fifty-two week low of $19.43 and a fifty-two week high of $40.83. The company has a debt-to-equity ratio of 0.20, a current ratio of 16.50 and a quick ratio of 16.51.
In related news, insider Gerrit Klaerner sold 8,000 shares of Tricida stock in a transaction on Monday, March 4th. The shares were sold at an average price of $23.92, for a total value of $191,360.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Dawn Parsell Otto sold 2,000 shares of Tricida stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 151,794 shares of company stock worth $4,407,688.
A number of large investors have recently bought and sold shares of TCDA. Wells Fargo & Company MN purchased a new position in Tricida in the 3rd quarter valued at $170,000. Rhumbline Advisers purchased a new stake in shares of Tricida during the 3rd quarter worth $270,000. Bank of New York Mellon Corp purchased a new stake in shares of Tricida during the 3rd quarter worth $1,057,000. BlackRock Inc. boosted its position in shares of Tricida by 216.4% during the 3rd quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock worth $30,707,000 after purchasing an additional 687,414 shares in the last quarter. Finally, American International Group Inc. purchased a new stake in shares of Tricida during the 3rd quarter worth $237,000. Hedge funds and other institutional investors own 69.83% of the company’s stock.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Article: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.